New hope for stubborn blood cancers? tiny trial tests LSD1 blocker
NCT ID NCT04262141
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental daily pill called IMG-7289 in 4 adults with essential thrombocythemia or polycythemia vera who did not improve on standard therapy. The drug targets the LSD1 protein to help control high blood cell counts. Researchers are checking whether it can improve blood counts and reduce symptoms, while monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMG-7289 (a daily oral capsule that blocks the LSD1 protein to help control blood cell counts)
What this could lead to
If it works, this could offer a new treatment option for people with these rare blood cancers who haven't responded to standard therapies.
What could go wrong
This is a very small early-phase trial with only 4 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami
Miami, Florida, 33136, United States